Jin Medical International
Jin Medical International's revenue fell 12.0% to $21 million in fiscal 2025. Its operating margin was 2.9%, down from 15.5% a year earlier. Free cash flow was −$4 million.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.
Income statement
From fiscal 2021 to 2025, earnings per share fell 15.9% a year and net income 17.6% a year, as new shares raised the share count by 16% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 4 | 7 | 17 | 27 | 30 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | 8.7x | 44.9x | 539.1x | 15.2x | 1.5x |
| Current ratio | — | 3.3x | 3.5x | 2.5x | 1.9x |
| Quick ratio | — | 2.1x | 2.9x | 2.2x | 1.6x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 18.4% | 12.8% | −30.0% |
| Altman Z'' | 9.51 | 7.37 | 5.16 |
| Accruals ratio | −0.8% | 12.4% | −3.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Fail | Pass |
| Return on assets rose | — | Fail | Fail |
| Cash from operations exceeds net income | Pass | Fail | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | — | Fail | Fail |
| F-score | — | — | — |
Compare
Put Jin Medical International side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Jin Medical International | FY25 | −12.0% | 2.9% | −18.0% | — | — | — | |
| Spectral AI | FY25 | −33.6% | −43.8% | — | — | — | — | Compare |
| Lifeward | FY25 | −14.1% | −89.3% | −76.4% | — | — | — | Compare |
| DarioHealth | FY25 | −17.3% | −163.9% | −116.7% | — | — | — | Compare |
| Baird Medical Investment | FY25 | −39.1% | −113.7% | −6.2% | −50.0% | — | 1 | Compare |
5 years of figures
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 21 | 19 | 20 | 24 | 21 |
| Revenue growth | — | −7.6% | 3.3% | 18.6% | −12.0% |
| Gross profit | 6 | 6 | 7 | 10 | 6 |
| Research and development | 2 | 2 | 2 | 2 | 2 |
| Operating income | 3 | 2 | 3 | 4 | 1 |
| Net income | 3 | 3 | 3 | 4 | 1 |
| Diluted EPS (US$) | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 |
| Diluted shares (millions) | 135 | 135 | 145 | 156 | 156 |
| Cash flow | |||||
| Cash from operations | 6 | 2 | 3 | −1 | 3 |
| Capital expenditure | 0 | 0 | 0 | 0 | 7 |
| Free cash flow | 6 | 2 | 3 | −1 | −4 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | — | — | — | — | — |
| Balance sheet at fiscal year end | |||||
| Cash and short-term investments | 4 | 7 | 17 | 27 | 30 |
| Debt incl. finance leases | — | — | — | — | — |
| Total assets | — | 21 | 33 | 46 | 53 |
| Total liabilities | — | 6 | 9 | 17 | 24 |
| Shareholders' equity | 14 | 15 | 24 | 29 | 30 |
| Margins and ratios | |||||
| Gross margin | 30.6% | 32.3% | 34.2% | 40.4% | 29.2% |
| Operating margin | 12.7% | 11.1% | 14.5% | 15.5% | 2.9% |
| Net margin | 12.7% | 14.1% | 14.5% | 15.6% | 5.8% |
| Free cash flow margin | 27.9% | 8.0% | 15.1% | −5.8% | −18.0% |
| Rule of 40 (growth + FCF margin) | — | 0.5% | 18.4% | 12.8% | −30.0% |
| Return on capital | — | — | — | — | — |
| Return on equity | — | — | 14.7% | 13.9% | 4.1% |
| Return on assets | — | — | 10.7% | 9.3% | 2.4% |
| Net debt to EBITDA | — | — | — | — | — |